急性重症哮喘的临床治疗效果  

Analysis of Clinical Treatment Effect of Acute Severe Asthma

作　　者：李倩影[1] 肖桂贤[1] 郭福莹 LI Qianying;XIAO Guixian;GUO Fuying(The Second Affiliated Hospital of Shenyang Medical College,Shenyang 110035,China)

机构地区：[1]沈阳医学院附属第二医院,辽宁沈阳110035

出　　处：《中国医药指南》2021年第4期51-52,共2页Guide of China Medicine

摘　　要：目的对急性重症哮喘的临床治疗方法与效果进行分析和探讨。方法于2018年3月至2019年3月收治的急性重症哮喘患者100例展开研究,使用电脑随机双盲法将患者随机分为两组,每组各50例,对照组接受常规治疗,观察组在对照组的基础上给予布地奈德、异丙托溴铵治疗。比较两组患者治疗前后肺功能改善情况以及不良反应发生率,结果观察组患者PEF、FEV1水平分别为(361.82±22.79)L/min、(3.13±1.27)L,显著高于对照组的(315.09±21.38)L/min、(2.22±1.58)L,数据差异显著(P<0.05)。两组患者不良反应发生率比较差异不大(P>0.05)。结论在传统治疗方式的基础上,针对急性重症哮喘患者给予布地奈德联合异丙托溴铵进行治疗,能够显著提高患者治疗后的肺功能,提升治疗效果,值得临床推广使用。Objective To analyze and discuss the clinical treatment and effect of acute severe asthma.Method From March 2018 to March 2019,100 patients with acute severe asthma were randomly divided into two groups,50 cases in each group.The control group received conventional treatment,and the observation group received budesonide and ipratropium bromide on the basis of the control group.The improvement of lung function and adverse reactions of the two groups before and after treatment were compared.Results The levels of PEF and FEV1 in the observation group were(361.82±22.79)L/min and(3.13±1.27)L,respectively,which were significantly higher than those in the control group(315.09±21.38)L/min and(2.22±1.58)L,with significant data differences(P<0.05).There was little difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion On the basis of traditional treatment,budesonide combined with ipratropium bromide in the treatment of patients with acute severe asthma can significantly improve the lung function of patients after treatment,improve the treatment effect,which is worthy of clinical application.

关 键 词：急性重症哮喘 内科 综合治疗 疗效 

分 类 号：R562.25[医药卫生—呼吸系统]